NCT02715570

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Pulmocide Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945

Conditions

• Aspergillosis

Interventions

Type	Name	Description
DRUG	PC945 - single doses	Safety and tolerability of single doses
DRUG	Placebo - single doses	Safety and tolerability of single doses
DRUG	PC945 - repeat doses	Safety and tolerability of repeat doses
DRUG	Placebo - repeat doses	Safety and tolerability of repeat doses

Timeline

• Start date: 2017-10-23
• Primary completion: 2018-04-27
• Completion: 2018-04-27
• First posted: 2016-03-22
• Last updated: 2018-05-01

Locations

1 site across 1 country: United Kingdom